Alprostadil - PowderJectAlternative Names: Prostaglandin E1 - PowderJect
Latest Information Update: 13 Dec 2000
At a glance
- Originator PowderJect Pharmaceuticals; PowderJect Therapeutics
- Developer Evotec AG; PowderJect Pharmaceuticals; PowderJect Therapeutics
- Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin E1 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Erectile dysfunction